Mark D. Pegram, MD

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Pegram on the Development of Trastuzumab Biosimilars

April 29th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford's Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women's Cancer Center, discusses the development of trastuzumab biosimilars.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Pegram Discusses Challenges Once Biosimilars Hit US Market

January 19th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses challenges biosimilars will face once they hit the United States market.

Dr. Pegram on the Manufacturing Process of Biosimilars

December 6th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.

Dr. Pegram on Projections of Cost Reductions With Biosimilars

December 4th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses projections of cost reductions with biosimilars.

Dr. Pegram on Future Impact of Biosimilars in Oncology

November 13th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer

May 11th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

April 2nd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

September 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

August 11th 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

July 15th 2017

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer

February 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

May 21st 2015

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Dr. Pegram on a Phase II Trial of MGAH22 in Breast Cancer

June 1st 2014

Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.

Dr. Pegram on Combining Trastuzumab and Pertuzumab

April 26th 2013

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes the combination of pertuzumab and trastuzumab as a treatment for patients with HER2-positive metastatic breast cancer.